A community computational challenge to predict the activity of pairs of compounds Citation

Recent therapeutic successes have renewed interest in drug combinations, but experimental screening approaches are costly and often identify only small numbers of synergistic combinations. The DREAM consortium launched an open challenge to foster the development of in silico methods to computationally rank 91 compound pairs, from the most synergistic to the most antagonistic, based on gene-expression profiles of human B cells treated with individual compounds at multiple time points and concentrations. Using scoring metrics based on experimental dose-response curves, we assessed 32 methods (31 community-generated approaches and SynGen), four of which performed significantly better than random guessing. We highlight similarities between the methods. Although the accuracy of predictions was not optimal, we find that computational prediction of compound-pair activity is possible, and that community challenges can be useful to advance the field of in silico compound-synergy prediction.

[1]  Claudio Cobelli,et al.  Function-Based Discovery of Significant Transcriptional Temporal Patterns in Insulin Stimulated Muscle Cells , 2012, PloS one.

[2]  Xiaobo Zhou,et al.  An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data , 2011, Bioinform..

[3]  Yujin Hoshida,et al.  Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment , 2010, PloS one.

[4]  Philip Resnik,et al.  Semantic Similarity in a Taxonomy: An Information-Based Measure and its Application to Problems of Ambiguity in Natural Language , 1999, J. Artif. Intell. Res..

[5]  Jason Weston,et al.  Gene Selection for Cancer Classification using Support Vector Machines , 2002, Machine Learning.

[6]  Xing-Ming Zhao,et al.  Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..

[7]  Christian von Mering,et al.  STITCH: interaction networks of chemicals and proteins , 2007, Nucleic Acids Res..

[8]  Ramakrishna Ramaswamy,et al.  A robust meta-classification strategy for cancer diagnosis from gene expression data , 2005, 2005 IEEE Computational Systems Bioinformatics Conference (CSB'05).

[9]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[11]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Stein Ge,et al.  Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination. , 1984 .

[13]  H. Nelson,et al.  Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. , 2001, The Journal of allergy and clinical immunology.

[14]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[15]  M. Shah,et al.  Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  Taher Abbasi,et al.  Suppression of Signal Transducer and Activator of Transcription 3 Activation by Butein Inhibits Growth of Human Hepatocellular Carcinoma In Vivo , 2010, Clinical Cancer Research.

[17]  Roded Sharan,et al.  Combining Drug and Gene Similarity Measures for Drug-Target Elucidation , 2011, J. Comput. Biol..

[18]  Carol Friedman,et al.  Drug-drug interaction through molecular structure similarity analysis , 2012, J. Am. Medical Informatics Assoc..

[19]  Mariano J. Alvarez,et al.  A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers , 2010, Molecular systems biology.

[20]  Adam A. Margolin,et al.  Prognostic Models for Breast Cancer Systematic Analysis of Challenge-Driven Improvements in Molecular , 2013 .

[21]  John P. Overington,et al.  A ligand's-eye view of protein similarity , 2013, Nature Methods.

[22]  R. Sharan,et al.  PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.

[23]  I. Weinstein Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[24]  Yoshihiro Yamanishi,et al.  Supervised prediction of drug–target interactions using bipartite local models , 2009, Bioinform..

[25]  Michael Costanzo,et al.  Systematic exploration of synergistic drug pairs , 2011, Molecular systems biology.

[26]  J R Bertino,et al.  5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Ravi Salgia,et al.  Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer , 2008, Journal of carcinogenesis.

[28]  Andrea Califano,et al.  Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. , 2013, Cancer cell.

[29]  P. Jänne,et al.  Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab , 2011, Science Translational Medicine.

[30]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[31]  J. Lehár,et al.  Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.

[32]  G E Stein,et al.  Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination. , 1984, Clinical pharmacy.

[33]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[34]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[35]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[36]  A. Massey,et al.  γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments , 2014, BMC Cancer.

[37]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Anne E Carpenter,et al.  ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. , 2014, Cell reports.

[39]  R P Araujo,et al.  A mathematical model of combination therapy using the EGFR signaling network. , 2005, Bio Systems.

[40]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[41]  Sampsa Hautaniemi,et al.  Fast Gene Ontology based clustering for microarray experiments , 2008, BioData Mining.

[42]  David Dunson,et al.  Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[43]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[44]  Fernanda Borges,et al.  Combining QSAR classification models for predictive modeling of human monoamine oxidase inhibitors. , 2013, European journal of medicinal chemistry.

[45]  M. Tsao,et al.  Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines. , 1996, Lung cancer.

[46]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[47]  Temple F. Smith,et al.  The statistical distribution of nucleic acid similarities. , 1985, Nucleic acids research.

[48]  Lei He,et al.  PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.

[49]  Avner Schlessinger,et al.  Improved Disorder Prediction by Combination of Orthogonal Approaches , 2009, PloS one.

[50]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[51]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[52]  N. D. Clarke,et al.  Towards a Rigorous Assessment of Systems Biology Models: The DREAM3 Challenges , 2010, PloS one.

[53]  Kara Dolinski,et al.  The BioGRID Interaction Database: 2011 update , 2010, Nucleic Acids Res..

[54]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .

[55]  R. Norel,et al.  The self-assessment trap: can we all be better than average? , 2011, Molecular systems biology.

[56]  Ravi Iyengar,et al.  Systems Pharmacology of Adverse Event Mitigation by Drug Combinations , 2013, Science Translational Medicine.

[57]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[58]  A. Recht,et al.  Radiotherapy and surgery in early breast cancer. , 1996, The New England journal of medicine.

[59]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[60]  C. Steinbeck,et al.  Recent developments of the chemistry development kit (CDK) - an open-source java library for chemo- and bioinformatics. , 2006, Current pharmaceutical design.

[61]  Mariano J. Alvarez,et al.  Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. , 2014, Cancer cell.

[62]  Diogo M. Camacho,et al.  Wisdom of crowds for robust gene network inference , 2012, Nature Methods.